Interaction between naltrexone and oral THC in heavy marijuana smokers

Psychopharmacology

Volumn 166, Issue 1, 2003, Pages 77-85

  Haney, Margaret ^a   Bisaga, Adam ^a   Foltin, Richard W ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Cannabinoid; Choice; Marijuana; Methadone; Opioid

Indexed keywords

DRONABINOL; METHADONE; NALTREXONE; PLACEBO;

ADULT; ARTICLE; CANNABIS ADDICTION; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA AND VOMITING; NORMAL HUMAN; PRIORITY JOURNAL; PUPIL; RECEPTOR BLOCKING; REINFORCEMENT; STOMACH DISEASE; TASK PERFORMANCE;

EID: 0037294170     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1279-8     Document Type: Article

References (48)

1. Beardsley PM, Balster RL, Harris LS (1986) Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 239:311-319
2. Braida D, Pozzi M, Parolaro D, Sala M (2001) Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 413:227-234
3. Castaneda E, Moss DE, Oddie SD, Whishaw IQ (1991) THC does not affect striatal dopamine release: microdialysis in freely moving rats. Pharmacol Biochem Behav 40:587-591
4. 9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156-162
5. Chen J, Paredes W, Lowinson JH, Gardner EL (1991) Strain-specific facilitation of dopamine efflux by Δ9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 129:136-140
6. Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, Sexton T, Ward S (1992) Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann NY Acad Sci 654:33-51
7. Comer SD, Collins ED, Wilson ST, Donovan MR, Foltin RW, Fischman MW (1998) Effects of an alternative reinforcer on intravenous heroin self-administration by humans. Eur J Pharmacol 345:13-26
8. 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol 323:193-195
9. Di Chiara G (1995) The role of dopamine in drag abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95-137
10. Dingledine R, Iversen LL, Breuker E (1978) Naloxone as a GABA antagonist: evidence from iontophomtic, receptor binding and convulsant studies. Eur J Pharmacol 47:19-27
11. Evans SM, Troisi JR II, Griffiths RR (1994) Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 271:683-694
12. Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW (1998) Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology 19:499-516
13. Foltin RW, Evans SM (1993) Performance effects of drugs of abuse: a methodological survey. Hum Psychopharmacol 8:9-19
14. Foltin RW, Haney M, Comer SD, Fischman MW (1996) Effect of fluoxetine on food intake of humans living in a residential laboratory. Appetite 27:165-181
15. 1 receptors. Eur J Pharmacol 341:39-44
16. Greenwald MK, Stitzer ML (2000) Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59:261-275
17. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a) Abstinence symptoms following oral THC in humans. Psychopharmacology 141:385-394
18. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404
19. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322-328.
20. 9-tetrahydrocannabinoltolerant rats. Psychopharmacology 55:243-249
21. 9-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 41:118-129
22. Ledent C, Valverde O, Cossu, Petitet F, Aubert J-F, Beslot F, Bohme GA, Imperator A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404
23. Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
24. Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in Δ9-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298:1007-1014
25. 9-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers. Drug Alcohol Depend 64:143-149
26. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA (1998) Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Mol Brain Res 55:126-132
27. Mason DJ, Lowe J, Welch SP (1999) A diminution of Δ9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. Eur J Pharmacol 381:105-111
28. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
29. Meyer MC, Straughn AB, Lo M-W, Schary WL, Whitney CC (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45:15-19
30. Nahas GG, Harvey DJ, Sutin KM (2000) Psychoactive cannbinoids and membrane signaling. Hum Psychopharmacol Clin Exp 15:535-549
31. Navarro M, Chowen J, Carrera MRA, del Arco I, Villanúa MA, Martin Y, Roberts AJ, Koob GF, Rodríguez de Fonseca F (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. NeuroReport 9:3397-3402
32. Navarro M, Carrera MRA, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gómez R, del Arco I, Villanúa MA, Maldonado R, Koob GF, Rodríguez de Fonseca F (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21:5344-5350
33. Oncken C, Van Kirk J, Kranzler HR (2001) Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154:397-402
34. 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 301:75-81
35. 9tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors. Eur J Pharmacol 318:11-16
36. 1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 66:2213-2219
37. 35S]GTPγS autoradiography in rat brain. J Neurosci 16:2684-2692
38. 35S]GTPγS autoradiography in rat brain. J Neurosci 16:8057-8066
39. A/benzodiazepine receptor function in rat corticohippocampal synatoneurosomes. J Neural Transm 107:261-270
40. 1-opioid receptor mechanism. Science 276:2048-2050
41. 9tetrahydrocannabinol in rats. Eur J Pharmacol 70:219-224
42. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A (2000) Cannabinoid withdrawal syndrome is reduced in preproenkephalin knock-out mice. J Neurosci 20:9284-9289
43. Vásquez C, Lewis DK (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280
44. Vela G, Ruiz-Gayo M, Fuentes JA (1995) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34:665-668
45. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH (1998) Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR141716A. J Pharmacol Exp Ther 286:697-703
46. 9-tetrahydrocannabinol in humans. Drug Alcohol Depend 59:251-260
47. Wall ME, Brine DR, Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 5:369-375
48. Welch SP, Thomas C, Patrick GS (1995) Modulation of cannabinoid antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272:310-321